Dr Caroline Coats

  • Honorary Clinical Senior Lecturer (School of Cardiovascular & Metabolic Health)

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2018
Number of items: 7.

2024

Masri, A. et al. (2024) Efficacy and safety of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2024.02.020) (PMID:38493832) (In Press)

Goldie, F. C., Lee, M. M. Y. , Coats, C. J. and Nordin, S. (2024) Advances in multi-modality imaging in hypertrophic cardiomyopathy. Journal of Clinical Medicine, 13(3), 842. (doi: 10.3390/jcm13030842) (PMID:38337535) (PMCID:PMC10856479)

2023

Glen, C., Adam, S., Coats, C. J. and Lang, N. N. (2023) Reply: Cardiotoxicity of BRAF/MEK inhibitors according to HFA/ICOS cardiotoxicity risk category. JACC: CardioOncology, 5(6), p. 850. (doi: 10.1016/j.jaccao.2023.10.003) (PMID:38204997) (PMCID:PMC10774785)

Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)

Maron, M. S. et al. (2023) Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 81(1), pp. 34-45. (doi: 10.1016/j.jacc.2022.10.020) (PMID:36599608)

2022

Coats, C. J. (2022) History of the British Cardiovascular Society. Heart, 108(10), pp. 761-766. (doi: 10.1136/heartjnl-2021-320139) (PMID:35459725)

2018

Jackson, A. M., Dalzell, J. R., Walker, N. L., Coats, C. J. , Jhund, P. S. and Petrie, M. C. (2018) Peripartum cardiomyopathy: diagnosis and management. Heart, 104(9), pp. 779-786. (doi: 10.1136/heartjnl-2016-310599) (PMID:29122930)

This list was generated on Sat Jul 20 12:13:38 2024 BST.
Jump to: Articles
Number of items: 7.

Articles

Masri, A. et al. (2024) Efficacy and safety of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2024.02.020) (PMID:38493832) (In Press)

Goldie, F. C., Lee, M. M. Y. , Coats, C. J. and Nordin, S. (2024) Advances in multi-modality imaging in hypertrophic cardiomyopathy. Journal of Clinical Medicine, 13(3), 842. (doi: 10.3390/jcm13030842) (PMID:38337535) (PMCID:PMC10856479)

Glen, C., Adam, S., Coats, C. J. and Lang, N. N. (2023) Reply: Cardiotoxicity of BRAF/MEK inhibitors according to HFA/ICOS cardiotoxicity risk category. JACC: CardioOncology, 5(6), p. 850. (doi: 10.1016/j.jaccao.2023.10.003) (PMID:38204997) (PMCID:PMC10774785)

Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)

Maron, M. S. et al. (2023) Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 81(1), pp. 34-45. (doi: 10.1016/j.jacc.2022.10.020) (PMID:36599608)

Coats, C. J. (2022) History of the British Cardiovascular Society. Heart, 108(10), pp. 761-766. (doi: 10.1136/heartjnl-2021-320139) (PMID:35459725)

Jackson, A. M., Dalzell, J. R., Walker, N. L., Coats, C. J. , Jhund, P. S. and Petrie, M. C. (2018) Peripartum cardiomyopathy: diagnosis and management. Heart, 104(9), pp. 779-786. (doi: 10.1136/heartjnl-2016-310599) (PMID:29122930)

This list was generated on Sat Jul 20 12:13:38 2024 BST.